Cannabis Law and Access in Chile

Chile's cannabis law: how the framework actually works

Forty-one countries now have some form of regulated cannabis access for non-recreational purposes. Chile was, quietly, one of the earlier movers in Latin America, and the structure its cannabis law landed on is worth understanding properly, not just in headline form.

I'll be upfront: this article is written from Canberra, for an Australian audience, and nothing in it is Australian legal advice. Chilean law has no direct bearing on what Australian patients, prescribers, or researchers can or cannot do under the Therapeutic Goods Administration's framework. If you're looking for how things work here, our pieces on the Special Access Scheme and Authorised Prescriber pathway are the right starting point. But for anyone trying to understand how global reform is playing out, and Chile is a genuinely interesting case, read on.

A note on method. Comparing foreign systems is easy to get wrong, because the same word can mean different things in different legal cultures. "Legal", "regulated", "tolerated" and "decriminalised" are four separate states, and much of what follows is an effort to keep them apart. For a wider look at why the labels matter, see our explainer on the medicinal versus recreational legal distinction.

The legislative foundation

Chile's primary drug control statute is Law 20.000, enacted in 2005, which regulates the production, trafficking, and possession of controlled substances. Cannabis sits within that law as a controlled plant, and simple possession for personal use carries legal risk, though enforcement has been patchy in practice, particularly for small amounts. The critical word there is "patchy": it is not decriminalised in the strict legal sense, and the distinction matters.

Why does it matter? Decriminalisation is a statement in the law itself that an act no longer attracts criminal penalties. Patchy enforcement is only a description of how police and prosecutors behave on a given day. The first gives a person certainty. The second gives them none, because practice can shift without Parliament doing anything at all.

The more significant shift came with amendments to Law 20.000 and the separate regulatory work under the Instituto de Salud Pública de Chile (ISP), the country's public health regulator. In 2015, Chile authorised the first domestic trials of cannabis-based products for specific patient groups. Then in 2022, Law 21.394 amended the legal framework to expand, within limits, the space for regulated medical use and licensed domestic cultivation.

The short version is this: medical use under ISP authorisation is legal. Recreational use is not, and home cultivation without an ISP licence remains prohibited. A bill to legalise personal adult-use cultivation passed the Chilean Chamber of Deputies in 2023 but was still moving through the Senate as of mid-2024. So the situation is live and changing.

Who can access cannabis products, and how

Chilean patients can access cannabis-based products through pharmacies under a medical prescription. The ISP classifies cannabis-derived products, including those containing THC and cannabidiol, and authorised products must meet documented quality standards roughly analogous to what we'd call Good Manufacturing Practice compliance here. Imported products need ISP registration. Domestically produced products require a cultivation and processing licence from the ISP.

The pattern is a familiar one. A prescriber is involved, a pharmacy supplies, and the regulator sits upstream deciding which products are eligible at all. Australian readers will recognise the broad shape from our own system, even though the legal mechanics differ. Our guide to the Therapeutic Goods Administration sets out the local version of that upstream role.

In practice, the available product range includes oils, capsules, and standardised extracts. Flower for smoking is in a more complicated regulatory position and is not freely available through the pharmacy channel in the same way. The standardised extract model is the dominant commercial form. A standardised extract is simply one produced so that its stated cannabinoid content is consistent from batch to batch, which is what makes documented quality standards workable for a regulator.

There is also an established "medicinal cannabis club" structure, clubes cannábicos, that operated in a legal grey zone for years before the 2022 reforms. These are closed associations where members collectively cultivate for shared non-commercial use. Their status under the current law is contested, and the ISP has not issued clear formal guidance that legalises them outright, even though police enforcement against them diminished significantly after 2015. A grey zone is not a safe harbour, and I'd caution against reading tolerance as permission.

Cultivation licensing and the domestic industry

Chile's climate and geography make it well-suited to cannabis cultivation, and the domestic industry has attracted genuine investment. The ISP issues licences for research, cultivation, and industrial hemp separately. Hemp, defined in Chilean regulation as cannabis with low THC content, broadly in line with international norms, has an agricultural licence pathway distinct from medicinal cannabis.

Separate licence categories are a sensible design choice. A research licence, a cultivation licence and a hemp licence each carry different obligations around record-keeping, site security and end use, so folding them into one permit would blur what a regulator is actually supervising. When reading any country's licensing rules, the first thing to check is which activity each licence authorises, and whether a licence for one activity quietly covers another. Usually it does not.

Chilean export of cannabis-derived products to other markets has grown, particularly to European destinations. The country's southern hemisphere growing season and relatively lower production costs have attracted interest. From a regulatory standpoint, Chilean exporters must meet both ISP requirements domestically and the import country's standards, which for most European markets means EU-GMP equivalency.

That dual burden is the hard yards of cross-border trade: a product can be fully compliant at home and still be refused at the destination. The same logic applies to Australia, where an overseas approval does not stand in for local requirements.

I find this aspect of Chile's position genuinely interesting. It's one of the few South American nations to have built a working export-grade regulatory apparatus without first legalising adult-use. Whether that's sustainable long-term, or whether the unresolved personal-use question creates ongoing legal friction that investors eventually find too uncomfortable, is worth watching. For a neighbouring comparison, our piece on cannabis law in Colombia shows a different route through similar questions.

The cannabinoid profile question

Chilean regulation addresses the cannabis plant broadly rather than enumerating individual cannabinoids with precision, which creates some ambiguity for minor cannabinoids. Products containing predominantly CBD are available, as are products with varying THC:CBD ratios. There is no explicit regulatory carve-out for cannabinoids like cannabigerol in the way some other jurisdictions are now starting to develop, though ISP product registration in principle covers any cannabis-derived substance requiring approval.

Plant-level regulation has a trade-off. It is simple to administer and does not need amending each time a new compound attracts attention, but it leaves businesses and clinicians guessing about where a minor cannabinoid sits until the regulator says so. Rules that name compounds individually are clearer, though they date faster.

The endocannabinoid system underpins the biological rationale for cannabis-derived products regardless of jurisdiction, and Chilean researchers have been active in relevant pharmacology work. The Universidad de Chile and Pontificia Universidad Católica de Chile have both published in this space. But for a reader interested in the science rather than the law, the regulatory framework only tells you what's permitted. The mechanism of how these compounds interact at the CB1 receptor and CB2 receptor level is the same in Santiago as it is in Sydney.

That is also a reminder about evidence. A product being lawful in one country says nothing about the strength of research behind it; approval pathways and evidence standards are different things. If you want to understand how researchers separate stronger evidence from weaker, our explainer on randomised controlled trials is a good place to start.

Enforcement, personal use, and practical reality

I want to be careful here, because "enforcement is patchy" is not the same as "it's fine." Possession of cannabis without a prescription or documented affiliation with a licensed club remains a criminal offence under Law 20.000. Penalties can include fines and, for quantities deemed to indicate supply rather than personal use, imprisonment. The threshold between personal use and supply is not precisely codified; it's left to prosecutorial and judicial discretion, which is exactly the kind of ambiguity that creates real legal risk for individuals even when aggregate enforcement rates appear low.

Aggregate figures can mislead here. A low overall enforcement rate tells you about the system, not about the person standing in front of a prosecutor. Where the line between use and supply is left to discretion, two people with similar circumstances can end up with very different outcomes, and neither can know in advance which way it will go.

This is not a situation I'd encourage anyone to treat lightly, least of all Australian travellers, for whom the consular assistance framework from the Department of Foreign Affairs and Trade is limited once you're facing drug charges abroad.

The proposed legalisation bill moving through the Senate would change this picture materially: it includes provisions for personal cultivation of up to six plants and possession of up to 10 grams without criminal liability. But a bill in the Senate is not law, and the timeline for passage (and presidential assent) remains uncertain. Treat any summary of a pending bill, including this one, as a snapshot rather than a forecast.

What AU readers should take from this

The honest answer is: awareness, not application. Chile's framework is interesting as a data point in global reform, and for researchers or policy analysts tracking how different regulatory models perform, it's a legitimate comparator. Its long, isolated geography has always produced distinctive policy paths, and it is a fair reminder that regulatory culture is shaped by local history rather than copied from a template.

For Australian access, the TGA's framework, the Schedule 8 (Controlled Drug) classification for THC-containing products, the Schedule 4 pathway for lower-risk formulations, and the SAS and Authorised Prescriber routes, remains the operative law. Our overviews of the Special Access Scheme in Australia and the legal basis for unapproved therapeutic goods explain how those routes sit within the Act. The regulator's own site, tga.gov.au, is the authority for current requirements.

Products approved in Chile carry no automatic standing under the Australian Register of Therapeutic Goods; the ARTG is its own sovereign instrument. The most common mistake I see in cross-border commentary is assuming that a foreign approval, a foreign licence or a foreign tolerance of personal use somehow travels. None of them do.

My view, for what it's worth: Chile's model is more coherent than it's often given credit for in international commentary, but the unresolved personal-use question is a structural problem the current government will have to address eventually. A medical framework that sits alongside an effectively unenforced but technically criminal personal-use landscape is an uncomfortable halfway house.

Sources

• Law 21.394 (2022 cannabis reform), Biblioteca del Congreso Nacional de Chile
• Cannabis Medicinal, Instituto de Salud Pública de Chile
• Cannabis policy: status and recent developments; European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
• Guidance on access to unapproved therapeutic goods, Therapeutic Goods Administration (TGA)

Marcus Hale, Regulatory researcher, TGA & access law